Sign In
Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
VERV.US
On November 7, 2022, Verve (VERV) announced that the FDA placed a hold on the company's Investigational New Drug (IND) application, halting a potential clinical trial for VERVE-101 to treat patients with heterozygous familial hypercholesterolemia (HeFH), a type of atherosclerotic cardiovasculorphan disease.

Verve had planned to use its gene-editing medicine to turn off the PCSK gene in the liver to reduce lipoprotein cholesterol (LDL-C), known to cause cardiovascular disease by building up in the arteries, leading to reduced blood flow or blockages and eventually, a heart attack or stroke.

On this news, VERV shares dropped more than 30% and the Company lost over $0.5 billion of its capitalization, seriously damaging shareholers.
Alleged Offence
Misleading Statements
Failure to Disclose
Negligence
Breach of Fiduciary duty
Omissions
Suspected Party
Directors
Management
Government Authority
Service Provider
Security Type
Stocks
Trade Direction
Long
Shock Event Date
07 November 2022
Collecting participants…
Created by Stan Vick, Scout

Verve Therapeutics Inc

Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-...

    Ticker
    VERV.US
    ISIN
    US92539P1012
    CIK
    1840574
    Sector
    Healthcare
    Industry
    Biotechnology
    Country
    USA
    Address
    500 Technology Square, Cambridge, MA, United States, 02139